JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Thromboangiitis obliterans (Buerger's disease) in 2 women].

In two female patients with an ischaemic peripheral disease, 49 and 32 years old, thromboangiitis obliterans (Buerger's disease) was diagnosed. One suffered from ulceration of her left second toe, the other from pain of both hands followed by ulceration of two fingers. Both were smokers. Surgical treatment (amputation) was required, and they also had a prostacyclin infusion. They recovered and stopped smoking. Thromboangiitis obliterans is a non-arteriosclerotic, segmental occlusive disease of medium-sized and small arteries and veins, occurring predominantly in young male habitual smokers. In the nineteen-seventy less than 2% were women, but recent publications mention 23%, an increase which may be attributed to increased smoking in women. Recognition of Buerger's disease in women with peripheral occlusive arterial disease is important; the prognosis is good if they stop smoking.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app